Vycavert

**Vycavert** was an investigational immediate-release fixed-dose oral analgesic tablet containing hydrocodone bitartrate and acetaminophen, developed by Acura Pharmaceuticals using its AVERSION abuse-deterrent technology. Hydrocodone provides opioid analgesia through mu-opioid receptor agonism, while acetaminophen provides non-opioid analgesic activity. The AVERSION formulation incorporated tamper-deterrent features intended to discourage intranasal and intravenous misuse of crushed tablets. Clinical studies evaluated oral bioequivalence against Norco and the abuse potential of intranasally administered crushed Vycavert in non-dependent recreational opioid users. Acura's later LIMITx candidate LTX-03 is a distinct hydrocodone/acetaminophen formulation and should not be treated as the same product. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01456520))

Brand names

Vycavert

Other names

acetaminophen + hydrocodone bitartratehydrocodone bitartrate + acetaminophen